PATENT CLAIM ANALYSIS

Application Number: 15925830
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2019-03
Patent Classification: ["530", "300000"]

Abstract:
Disclosed is a drug conjugate as a prodrug that is degraded by cathepsin B specifically expressed in tumor tissues to release doxorubicin. The drug conjugate can form self-assembled nanoparticles. In addition, the drug conjugate specifically responds to and is activated in tumor cells. Therefore, the use of the drug conjugate eliminates the incidence of side effects (for example, cell damage and apoptosis) during the course of cancer prevention or treatment.

Claim (Index 5):
The drug conjugate according to  claim 2 , wherein the amphiphilic peptide has the sequence set forth in any one of SEQ ID NOS: 1 to 4.

Metadata:
- Claim Count in Document: 15.0
- Percentile: 90.0
- Lexical Diversity: 1.46296
- Patent Class: 530.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['14651860', '15446387', '14490336', '10659501', '13120140']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7109871862004001
- 35 USC 102 Novelty (BERT): 0.5194989871786867
- Combined Prediction Score: 0.6918383662982288
- Mean Citation Score: 290.175624
- Max Citation Score: 310.0214200000001
- Similarity Product: 201.9632810390807

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test